Radionuclide-protein conjugate and use thereof
TW202641872APending Publication Date: 2026-10-16BEIJING HEXIN PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW115111975
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-03-28
- Filing Date
- 2026-03-27
- Publication Date
- 2026-10-16
Smart Images
Figure TWG2TA001081304_001 
Figure TWG2TA001081304_002 
Figure TWG2TA001081304_003
Abstract
For example, a combination of mutations may be L234A, L235A, and H435Q. The fusion protein provided by the present disclosure, after chelating with a radionuclide, exhibits low-dose uptake and can be rapidly cleared in tissues such as blood, kidney, and liver, while achieving high-dose and long-duration uptake in tumor tissues. This significantly improves the safety and efficacy of the radiopharmaceutical treatment.
Need to check novelty before this filing date? Find Prior Art